Discussions

Question: I am a clinical epidemiologist taking an initial look at generics vs. brand drugs for depression. There are some concerns in the published literature regarding determining the requirements for bio-equivalence of "highly-variable" (HV) drugs.

At the upcoming G8 summit, Stephen Harper has stated he intends to champion an agenda that improves the health of women and children (aside from allowing full reproductive choices). This is part of the Millennium goals, on which all participants at the Summit will receive a score card on their progress. However, how well are we scoring on empowering and supporting the women physicians who in many parts of the world supply more than 50% of healthcare?

Putting the blame on ‘public attachment’ to existing health services and ‘insider interests’ may be a bit simplistic